Overview

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Status:
Terminated

Trial end date:
2015-05-07

Target enrollment:

Participant gender:

Summary

This open-label study is to determine the safety and efficacy of momelotinib in participants with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet received treatment with a Janus kinase (JAK) inhibitor.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences
Sierra Oncology, Inc.

Treatments:

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide